BBIO · BridgeBio Pharma
23 filings
BBIO 10-Q Quarterly Reports
BridgeBio Pharma - 23 quarterly reports
BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.
- 8-K · Jul 3, 2019
- 10-Q · Aug 14, 2019
- 8-K · Sep 12, 2019
- 8-K · Oct 11, 2019
- 10-Q · Nov 8, 2019
- 8-K · Nov 19, 2019
- 8-K · Dec 17, 2019
- 8-K · Dec 26, 2019
- 8-K · Jan 7, 2020
- 8-K · Feb 19, 2020
- 8-K · Mar 2, 2020
- 10-K · Mar 3, 2020
- 8-K · Mar 4, 2020
- 8-K · Mar 6, 2020
- 8-K · Mar 10, 2020
- 8-K · Mar 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · May 14, 2020
- 8-K · Jun 8, 2020
- 8-K · Jun 24, 2020
- 8-K · Aug 11, 2020
- 10-Q · Aug 11, 2020
- 8-K · Sep 29, 2020
- 8-K · Oct 5, 2020
- 8-K · Oct 6, 2020
- 8-K · Oct 23, 2020
- 10-Q · Nov 5, 2020
- 8-K · Nov 5, 2020
- 8-K · Nov 6, 2020
- 8-K · Jan 4, 2021
- 8-K · Jan 12, 2021
- 8-K · Jan 20, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 29, 2021
- 8-K · Feb 17, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Mar 31, 2021
- 8-K · Apr 15, 2021
- 10-Q · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 14, 2021
- 8-K · Jun 1, 2021
- 8-K · Jun 22, 2021
- 10-Q · Aug 5, 2021
- 8-K · Aug 13, 2021
- 8-K · Aug 23, 2021
- 8-K · Oct 26, 2021
- 8-K · Nov 4, 2021
- 10-Q · Nov 4, 2021
- 8-K · Nov 18, 2021
- 8-K · Dec 16, 2021
- 8-K · Dec 27, 2021
- 8-K · Feb 24, 2022
- 10-K · Feb 25, 2022
- 10-Q · May 5, 2022
- 8-K · May 10, 2022
- 8-K · May 13, 2022
- 8-K · May 18, 2022
- 8-K · Jun 24, 2022
- 8-K · Jul 26, 2022
- 10-Q · Aug 4, 2022
- 8-K · Aug 4, 2022
- 8-K · Sep 23, 2022
- 10-Q · Nov 3, 2022
- 8-K · Nov 3, 2022
- 8-K · Dec 6, 2022
- 8-K · Feb 23, 2023
- 10-K · Feb 23, 2023
- 8-K · Mar 6, 2023
- 8-K · Mar 9, 2023
- 8-K · May 4, 2023
- 10-Q · May 4, 2023
- 8-K · May 4, 2023
- 8-K · Jun 22, 2023
- 8-K · Jul 17, 2023
- 8-K · Aug 3, 2023
- 10-Q · Aug 3, 2023
- 8-K · Sep 25, 2023
- 10-Q · Nov 2, 2023
- 8-K · Nov 2, 2023
- 8-K · Jan 8, 2024
- 8-K · Jan 18, 2024
- 10-K · Feb 22, 2024
- 8-K · Feb 22, 2024
- 8-K · Mar 4, 2024
- 8-K · Mar 6, 2024
- 8-K · May 2, 2024
- 10-Q · May 2, 2024
- 8-K · Jun 6, 2024
- 8-K · Jun 24, 2024
- 8-K · Jul 23, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 1, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 11, 2024
- 10-Q · Nov 12, 2024
- 8-K · Nov 12, 2024
- 8-K · Nov 25, 2024
- 8-K · Jan 13, 2025
- 10-K · Feb 20, 2025
- 8-K · Feb 20, 2025
- 8-K · Feb 28, 2025
- 8-K · Mar 17, 2025
- 8-K · Apr 29, 2025
- 10-Q · Apr 29, 2025
- 8-K · Jun 23, 2025
- 8-K · Jul 2, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 27, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Oct 29, 2025
- 8-K · Jan 12, 2026
- 8-K · Jan 21, 2026
- 8-K · Feb 12, 2026
- 8-K · Feb 24, 2026
- 10-K · Feb 24, 2026
- 8-K · Mar 30, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 8, 2026
- 8-K · May 13, 2026
- 8-K · May 27, 2026
- 8-K · Jun 26, 2026
- 8-K · Jul 2, 2026
- 8-K · Jul 22, 2026
- 8-K · Aug 10, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 17, 2026
- 8-K · Aug 31, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
- 2026-Q3Oct 29, 2026
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2026
BridgeBio Pharma reported a sharply higher top line for the third quarter of 2026 while losses narrowed. Total revenues, net were $353.2 million for the three months ended September 30, 2026, compared with $120.7 million a year earlier, driven by net product revenue of $253.3 million for Attruby and a $75.0 million sales milestone under the Bayer License Agreement. Net loss was $60.5 million for the quarter versus $184.9 million a year earlier. Net loss attributable to common stockholders was $83.0 million after $26.3 million of preferred stock dividends and accretion, which reflect the Series A preferred stock issued July 1, 2026. For the nine months, total revenues were $791.4 million and net loss was $382.9 million, against $538.3 million in the prior-year period. The balance sheet and financing activity changed materially. Cash, cash equivalents and marketable securities were $1.54 billion at September 30, 2026, up from $587.5 million at December 31, 2025. Financing included $933.9 million from the Series A preferred stock, $632.5 million of 0.75% convertible notes due 2033, and $933.9 million in preferred proceeds. The company repurchased common stock and holds a $500.0 million share repurchase program, with $325.0 million remaining at quarter end per the filing's table. Total stockholders' deficit narrowed to $1.65 billion from $2.08 billion. Total debt includes $2.5 billion of convertible notes and $920.1 million of deferred royalty obligations. The 2027 Notes, $550.0 million principal, are classified as current and mature March 15, 2027. The filing names three NDAs with FDA Priority Review: oral BBP-418 for LGMD2I/R9 with a PDUFA date of November 27, 2026; encaleret for ADH1 with a PDUFA date of May 8, 2027; and low-dose infigratinib for achondroplasia with a PDUFA date of February 4, 2027. Management states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Operating cash outflow was $312.6 million for the nine months.
- 2026-Q2Aug 10, 2026
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2026
BridgeBio Pharma, Inc. reported a quarter ended June 30, 2026 with total revenues, net of $243.7 million for the three months, up from $110.6 million a year earlier, driven by net product revenue of $222.4 million (versus $71.5 million), which reflects Attruby. License and services revenue declined to $5.8 million from $37.4 million, as the prior-year period included a $30.0 million regulatory milestone. Net loss attributable to common stockholders was $152.2 million, or $(0.78) per share, compared with $181.9 million, or $(0.95) per share, in the prior-year quarter. For the six months, total revenues were $438.2 million and net loss attributable to common stockholders was $316.3 million. Operating expenses rose, with research and development at $149.4 million and selling, general and administrative expenses at $186.3 million for the quarter. Cash, cash equivalents and marketable securities totaled $720.2 million at June 30, 2026, against total debt of approximately $2.5 billion in convertible notes plus $908.7 million of deferred royalty obligations. The company issued $632.5 million of 0.75% convertible notes due 2033 in January 2026, and stockholders' deficit stood at $(2.5) billion. The company states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Subsequent to quarter-end, on July 1, 2026, BridgeBio sold 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million in gross proceeds to Sixth Street-affiliated and KKR-affiliated purchasers, at a 7.00% initial dividend rate and a $137.79 initial conversion price. The company also disclosed a $500.0 million at-the-market program and a $500.0 million share repurchase program approved in May 2026, under which it repurchased 1,904,001 shares for approximately $127.5 million through June 30, 2026. Regulatory milestones include a PDUFA target action date of November 27, 2026 for BBP-418 and May 8, 2027 for encaleret.
- 2026-Q1May 7, 2026
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2026
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $166.6 million for the three months ended March 31, 2026, compared with $169.6 million in the same period of 2025. Total revenues, net were $194.5 million, up from $116.6 million, driven by net product revenue of $180.6 million (versus $36.7 million), while license and services revenue fell to $4.4 million from $79.7 million, which the filing attributes mainly to $75.0 million of milestone revenue recognized in 2025 following Beyonttra's EU approval. Royalty revenue rose to $9.5 million. Operating expenses increased, with selling, general and administrative expenses at $163.9 million (up from $106.4 million) and research and development at $126.6 million (up from $111.4 million). Net cash used in operating activities was $197.3 million. Balance sheet activity was dominated by financing. In January 2026 the company issued $632.5 million of 0.75% convertible senior notes due 2033 and used $82.5 million of proceeds to repurchase 1,081,825 shares of common stock. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $940.2 million, and the company reported stockholders' deficit of $2.27 billion, with the 2027 Notes classified as current. Management states that existing cash and marketable securities and Attruby revenue are expected to fund operations for at least the next 12 months. On May 6, 2026, the Board approved a stock repurchase program of up to $500.0 million. The filing also notes that the company submitted a New Drug Application to the FDA for oral BBP-418 for LGMD2I/R9 on March 30, 2026, and that the 2027 and 2031 Notes became convertible for a limited period from April 1, 2026 through June 30, 2026 after a conversion condition was met.
- 2025-Q3Oct 29, 2025
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2025
BridgeBio Pharma, Inc. reported its quarterly results for the period ended September 30, 2025 in this Form 10-Q. Total revenues, net were $120.7 million for the three months ended September 30, 2025, up from $2.7 million a year earlier, and $347.9 million for the nine months, up from $216.0 million. Net product revenue from Attruby was $108.1 million for the quarter and $216.4 million for the nine months. Net loss was $184.9 million for the quarter and $538.3 million for the nine months, compared with $164.3 million and $276.0 million in the prior-year periods. Net loss attributable to common stockholders was $532.1 million for the nine months, or $(2.79) per share. The balance sheet shows cash, cash equivalents and marketable securities of $645.9 million as of September 30, 2025, compared with $681.1 million at December 31, 2024. Total liabilities were $2.92 billion against total assets of $998.3 million, resulting in a total stockholders' deficit of $1.92 billion. The company issued $575.0 million of 1.75% convertible senior notes due 2031 in February 2025 and fully repaid its $450.0 million term loan, and it received $300.0 million from a royalty purchase agreement in June 2025. Deferred royalty obligations, net, stood at $836.1 million. Net cash used in operating activities was $389.5 million for the nine months. Management states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months. The filing describes ongoing restructuring charges of $8.8 million for the quarter, a noncash interest expense of $36.4 million on deferred royalty obligations, and a share repurchase of 1,405,411 shares for $48.3 million in February 2025. Management notes that it expects to continue incurring operating and net losses for at least the next several years.
- 2025-Q2Aug 5, 2025
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2025
BridgeBio Pharma, Inc. reported a net loss of $183.8 million for the three months ended June 30, 2025, compared with a net loss of $75.5 million in the same period of 2024, and a net loss of $353.4 million for the six months ended June 30, 2025 (versus $111.7 million a year earlier). Total revenues, net were $110.6 million for the quarter, including net product revenue of $71.5 million from Attruby in the U.S., license and services revenue of $37.4 million (which includes a $30.0 million regulatory milestone under the Eidos-Alexion License Agreement), and royalty revenue of $1.6 million from Beyonttra in the EU and Japan. Selling, general and administrative expenses rose to $129.2 million from $59.5 million, driven by commercial launch investments, while research and development expenses were $111.2 million, down from $114.7 million. The balance sheet shows cash, cash equivalents and marketable securities of $756.9 million as of June 30, 2025, against total liabilities of $2.86 billion and a total stockholders' deficit of $1.78 billion. Financing activity during the period included the issuance of $575.0 million of 1.75% convertible senior notes due 2031 and the repayment of the $450.0 million term loan under the Amended Financing Agreement. On June 27, 2025, the company sold a portion of its future royalties on Bayer's EU sales of acoramidis to royalty purchasers for $300.0 million in cash. The company states that its existing resources will fund operations for at least the next 12 months from the filing date, and that it expects to continue incurring operating and net losses for at least the next several years. During the quarter, the company's Attruby and Beyonttra commercial products were approved in the EU, Japan and UK, and the company implemented newly designed internal controls in connection with the commercial launch. Management concluded that disclosure controls and procedures were effective as of June 30, 2025.
- 2025-Q1Apr 29, 2025
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2025
BridgeBio Pharma, Inc. reported a net loss of $169.6 million for the three months ended March 31, 2025, compared with a net loss of $36.2 million in the prior-year period. Total revenues, net were $116.6 million, down from $211.1 million, as license and services revenue fell to $79.9 million from $211.1 million. Net product revenue from Attruby in the U.S. was $36.7 million, and the filing notes that the $75.0 million regulatory milestone from Bayer, recognized in license and services revenue, was received in April 2025. Research and development expense decreased to $111.4 million from $141.0 million, while selling, general and administrative expense rose to $106.4 million from $65.8 million, mainly reflecting commercial activities for Attruby. During the quarter the company issued $575.0 million of 1.75% convertible senior notes due 2031 and used the proceeds to fully repay the $450.0 million principal term loan under its Amended Financing Agreement, along with $48.3 million to repurchase 1,405,411 shares of common stock. Cash and cash equivalents declined to $540.6 million from $681.1 million at December 31, 2024. Total stockholders' deficit was $1.64 billion, and total liabilities were $2.52 billion. Management states it expects its cash, cash equivalents and restricted cash to fund operations for at least the next 12 months, and it expects continued operating and net losses for at least the next several years. The filing also notes that Attruby received FDA approval on November 22, 2024, Beyonttra was approved by the European Commission on February 10, 2025 and in Japan on March 27, 2025, and that the company is pursuing three late-stage candidates: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9.
- 2024-Q3Nov 12, 2024
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2024
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $164.3 million for the three months ended September 30, 2024 and $276.0 million for the nine months, compared with $482.9 million for the nine months ended September 30, 2023. Revenue for the nine months rose to $216.0 million from $7.6 million, driven mainly by $205.3 million of upfront license fee and services revenue under the Bayer Agreement and the KKC Agreement, while three-month revenue was $2.7 million. Cash and cash equivalents were $266.3 million and restricted cash was $139.4 million at September 30, 2024, and total stockholders' deficit was $1.22 billion. Net cash used in operating activities was $325.4 million for the nine months. The filing states that substantial doubt exists about the company's ability to continue as a going concern for one year from November 12, 2024. Management plans to alleviate this doubt by receiving a $500.0 million milestone payment under the Funding Agreement upon FDA approval of acoramidis, together with product revenues if approved. The company anticipates FDA approval in late November 2024 but cannot guarantee the approval, the timing of the payment, or the resulting product revenues, and may need to raise additional capital. During 2024 the company restructured its portfolio: it deconsolidated GondolaBio and BBOT (TheRas, Inc.), recognizing gains of $52.0 million and $126.3 million respectively, ceased development of BBP-631 for congenital adrenal hyperplasia, and terminated the Navire-BMS License Agreement. Its outstanding debt was $1.7 billion, including $747.5 million of 2029 Notes, $550.0 million of 2027 Notes, and a $450.0 million term loan under the Amended Financing Agreement, with a $70.0 million minimum qualified cash balance that was $78.0 million as of September 30, 2024.
- 2024-Q2Aug 1, 2024
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2024
BridgeBio Pharma, Inc. ("BridgeBio") reported a net loss of $111.7 million for the six months ended June 30, 2024, compared with $303.4 million in the same period of 2023, and a net loss of $75.5 million for the three months ended June 30, 2024. Six-month revenue was $213.3 million, up from $3.5 million a year earlier, driven mainly by $202.9 million recognized from the upfront license fees and services revenue under the Bayer Agreement and the KKC Agreement. Research and development expense rose to $255.7 million for the six months and selling, general and administrative expense rose to $125.3 million, reflecting commercialization readiness efforts. The three-month period also included a $126.3 million non-cash gain from deconsolidating TheRas, Inc. (BridgeBio Oncology Therapeutics), following its $200.0 million private equity financing in which BridgeBio's ownership fell to approximately 37.9%. At June 30, 2024, cash, cash equivalents and marketable securities totaled $447.8 million, with restricted cash of $139.4 million, largely escrowed under the Financing Agreement from asset sale proceeds. Total debt principal included $747.5 million of 2029 Notes, $550.0 million of 2027 Notes and a $450.0 million term loan under the Amended Financing Agreement, which was used to repay the prior term loan in January 2024. Stockholders' deficit improved to $1.08 billion from $1.34 billion at December 31, 2023, following public offerings that raised $314.8 million in net proceeds during the first half of 2024. The company stated that its cash and equivalents should fund operations for at least the next 12 months. A pending Funding Agreement would provide $500.0 million upon the first FDA approval of acoramidis, which had been submitted to the FDA on December 5, 2023.
- 2024-Q1May 2, 2024
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2024
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $36.2 million for the three months ended March 31, 2024, a substantial improvement from a net loss of $142.7 million in the prior-year period. Revenue rose to $211.1 million from $1.8 million, driven mainly by $201.2 million of upfront license fee and services revenue from the Bayer Agreement and the KKC Agreement, plus $9.9 million from the terminated Navire-BMS License Agreement. Research and development expenses increased to $141.0 million from $92.9 million, and selling, general and administrative expenses increased to $65.8 million from $31.1 million, including $14.0 million of nonrecurring deal-related expenses. The balance sheet strengthened over the quarter. Cash, cash equivalents and marketable securities were $519.7 million at March 31, 2024, compared with $375.9 million at December 31, 2023, supported by a $450.0 million Initial Term Loan under a Financing Agreement with Blue Owl Capital Corporation and about $315.3 million of net proceeds from public offerings. The company used the proceeds to fully repay its prior term loan, which carried a $26.6 million loss on extinguishment of debt. Total stockholders' deficit narrowed to $(1,037.4) million from $(1,343.0) million, and the accumulated deficit was $2.6 billion. The company stated it expects its existing resources to fund operations for at least the next 12 months. Key forward-looking items include a $500.0 million funding agreement payable upon first FDA approval of acoramidis, in exchange for a 5% royalty on global net sales of acoramidis, and a requirement to deposit 75% of proceeds from certain asset sales into an escrow account under the Financing Agreement. The company also recorded new restructuring plans with an estimated remaining $12.0 million to $16.0 million in charges. A subsequent event on April 30, 2024 was a $200.0 million private financing of BridgeBio Oncology Therapeutics, which the company is still evaluating.
- 2023-Q3Nov 2, 2023
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2023
BridgeBio Pharma, Inc. (BridgeBio) reported its Form 10-Q for the quarter ended September 30, 2023. Revenue was $4.1 million for the three months ended September 30, 2023 (versus $0.3 million a year earlier) and $7.6 million for the nine months (versus $75.8 million), with the prior-year period including the $110.0 million priority review voucher sale and the Navire-BMS upfront payment recognition. Net loss was $179.5 million for the quarter and $482.9 million for the nine months, compared with $344.1 million a year earlier. Research and development expense rose to $125.1 million for the quarter, and selling, general and administrative expense was $35.8 million. The company reported accumulated deficit of $2.4 billion and total stockholders' deficit of $1.2 billion as of September 30, 2023. As of September 30, 2023, BridgeBio held cash and cash equivalents of $505.2 million, restricted cash of $16.7 million and investments in equity securities of $38.1 million. Outstanding debt was $1.7 billion net of discounts and issuance costs, consisting of 2.25% convertible notes due 2029 ($747.5 million principal), 2.50% convertible notes due 2027 ($550.0 million principal) and a 9.0% term loan. During the nine months, the company raised capital through a March 2023 follow-on offering (net proceeds $143.0 million), at-the-market sales (net proceeds $65.0 million) and a September 2023 private placement (net proceeds $241.3 million). The filing states that cash and equivalents, restricted cash and equity investments are expected to fund operations for at least the next 12 months from the filing date. The company stated that it expects to keep incurring operating and net losses for at least the next several years, and that its ability to reach profitability depends heavily on successful development and commercialization of its product candidates. The filing states that the remaining restructuring charges are expected to be immaterial through the end of 2023, and that the company is not party to any material legal proceedings.
- 2023-Q2Aug 3, 2023
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2023
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $303.4 million for the six months ended June 30, 2023, compared with $203.9 million in the same period of 2022, and a net loss of $160.7 million for the three months ended June 30, 2023. Revenue was $3.5 million for the six months, down from $75.4 million a year earlier, which included a $110.0 million priority review voucher sale and $70.2 million of license revenue from the Navire-BMS License Agreement in 2022. Research and development expense was $200.3 million for the six months, versus $216.0 million in 2022, and selling, general and administrative expense was $67.2 million, versus $80.1 million, reflecting cost reductions tied to the restructuring initiative that began in January 2022. As of June 30, 2023, the company had cash, cash equivalents and marketable securities of $333.3 million, restricted cash of $19.9 million and investment in equity securities of $50.5 million. Total debt principal consisted of $747.5 million of 2029 Notes, $550.0 million of 2027 Notes and a $452.0 million term loan, and the company reported a total stockholders' deficit of $1.35 billion. Net cash used in operating activities was $257.7 million for the six months. The company stated that its existing cash, cash equivalents, marketable securities, restricted cash and equity investment should fund operations for at least the next 12 months from the filing date, and that it expects to keep incurring operating and net losses for at least the next several years. Subsequent to quarter-end, in July 2023 the company sold 800,000 shares of common stock under its 2023 ATM Agreement at $34.46 per share, for net proceeds of $27.2 million. The March 2023 follow-on offering of 8,823,530 shares at $17.00 per share generated net proceeds of $143.0 million during the period.
- 2023-Q1May 4, 2023
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2023
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $142.7 million for the three months ended March 31, 2023, compared with $201.3 million in the same period of 2022. Total revenue was $1.8 million, versus $1.7 million a year earlier, and consisted mainly of $1.7 million of license and services revenue from the Navire-BMS License Agreement. Research and development expense fell to $92.9 million from $107.6 million, and selling, general and administrative expense fell to $31.1 million from $43.7 million, which the filing attributes to reprioritization of development programs and cost streamlining under a restructuring initiative begun in January 2022. Liquidity improved during the quarter. The company ended the period with cash, cash equivalents and marketable securities of $441.5 million, restricted cash of $25.5 million and equity securities of $49.8 million. Net cash used in operating activities was $144.3 million, offset by $143.0 million in net proceeds from a March 2023 follow-on offering of 8,823,530 shares at $17.00 per share. The company states that its existing resources should fund operations for at least the next 12 months. Stockholders' deficit was $1.21 billion at quarter end, and outstanding debt was $1.7 billion net of discounts, comprising the 2029 Notes, 2027 Notes and a term loan. The filing also reports the deconsolidation of PellePharm following its assignment for liquidation and a $1.2 million related loss, and states that the company is not party to any material legal proceedings. Management expects to continue incurring operating and net losses for at least the next several years and estimates restructuring charges of $6.0 million to $9.0 million for fiscal 2023.
- 2022-Q3Nov 3, 2022
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2022
BridgeBio Pharma, Inc. reported a net loss of $344.1 million for the nine months ended September 30, 2022, compared with $434.2 million in the same period of 2021. Total revenue for the nine months was $75.8 million, driven mainly by $73.3 million of license and services revenue recognized from the Navire-BMS License Agreement, which included a $90.0 million upfront payment. Net loss for the three months ended September 30, 2022 was $140.2 million. Cash, cash equivalents and marketable securities totaled $558.3 million at September 30, 2022, down from $787.5 million at December 31, 2021, and the company reported net cash used in operating activities of $326.3 million for the nine months. The company states it expects its cash, cash equivalents, marketable securities and equity investment to fund operations for at least the next 12 months. The company recorded $36.1 million of restructuring, impairment and related charges for the nine months, following a January 2022 restructuring initiative that it estimates will total $36.1 million to $48.4 million for fiscal 2022. Other notable items include a $107.9 million net gain from the sale of a priority review voucher for $110.0 million gross, and a notice from Helsinn on August 23, 2022 of its intent to terminate the Amended QED-Helsinn License and Collaboration Agreement for convenience. Total stockholders' deficit was $1.13 billion at September 30, 2022, and total debt principal consisted of $747.5 million of 2029 convertible notes, $550.0 million of 2027 convertible notes and a term loan with principal of $429.9 million plus $8.5 million of payment-in-kind interest added to principal.
- 2022-Q2Aug 4, 2022
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2022
BridgeBio Pharma, Inc. reported a net loss of $203.9 million for the six months ended June 30, 2022, compared with $273.2 million for the same period in 2021. Total revenue for the six months was $75.4 million, driven mainly by $73.4 million of license and services revenue recognized from the Navire-BMS License Agreement, under which Navire received a $90.0 million upfront payment collected in June 2022. Research and development expense was $216.0 million for the six months, down from $224.5 million, and restructuring, impairment and related charges were $31.1 million, with the company estimating total 2022 restructuring charges of approximately $31.0 million to $33.0 million. A $107.9 million net gain from the sale of a priority review voucher for $110.0 million also contributed to results for the period. As of June 30, 2022, cash, cash equivalents and marketable securities totaled $688.6 million, plus an investment in equity securities of $27.1 million, compared with $787.5 million and $49.1 million at December 31, 2021. Net cash used in operating activities was $191.1 million for the six months. Total stockholders' deficit was $1.01 billion, and outstanding debt was $1.7 billion net of discounts and issuance costs, comprising the 2029 Notes, the 2027 Notes and a term loan under the Amended Loan Agreement. The company states that its cash and investments will fund operations for at least the next 12 months from the filing date, and it expects to continue incurring operating and net losses for at least the next several years. The filing also notes that the company does not expect product sales for the remainder of fiscal 2022 because selling activities for its approved products have transferred to partners, and that a May 2022 amendment to the Loan Agreement permitted the sale of the priority review voucher and required a $20.5 million prepayment following the BMS upfront payment.
- 2022-Q1May 5, 2022
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2022
BridgeBio Pharma, Inc. reported a net loss of $201.3 million for the three months ended March 31, 2022, compared with a net loss of $171.1 million in the same period of 2021. Net loss attributable to common stockholders of BridgeBio was $196.4 million, or $1.35 per share, versus $163.1 million, or $1.18 per share, a year earlier. Total revenue was only $1.7 million ($235 thousand license revenue and $1.5 million product sales), and the company stated it does not anticipate generating product sales for the rest of 2022 as selling activities for its approved products have transferred to partners. Research and development expense was $107.6 million and SG&A was $43.7 million, with $22.7 million in restructuring, impairment and related charges following a January 2022 restructuring initiative, for which the company estimates total 2022 charges of approximately $23.0 million to $25.0 million. Liquidity declined over the quarter. Cash, cash equivalents and marketable securities fell to $633.5 million at March 31, 2022 from $787.5 million at December 31, 2021, mainly due to $160.6 million of net cash used in operating activities. Investment in equity securities, mainly its LianBio stake, was $37.8 million. Total debt was $1.7 billion net of discounts, comprising the 2.25% 2029 Notes ($747.5 million principal), the 2.50% 2027 Notes ($550.0 million principal) and a 9.0% term loan ($450.0 million principal drawn). The company stated it expects its cash, marketable securities and equity investments to fund operations for at least the next 12 months, and that its stockholders' deficit was $1.04 billion. Management also noted that it expects continued operating and net losses over the next several years.
- 2021-Q3Nov 4, 2021
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2021
BridgeBio Pharma, Inc. ("BridgeBio") reported its quarterly results for the period ended September 30, 2021. Total revenue for the three months ended September 30, 2021 was $2.3 million ($2,344 thousand), compared with $8.1 million in the prior-year quarter, and net loss was $161.0 million ($161,016 thousand). For the nine months, total revenue was $56.8 million, driven mainly by $44.4 million of license revenue from the QED-Helsinn License and Collaboration Agreement and $8.5 million from a regulatory milestone under the Navire-LianBio License Agreement. Nine-month net loss was $434.2 million, and research and development expense rose to $328.8 million from $246.9 million. The company stated that its two approved products, NULIBRY (fosdenopterin) and TRUSELTIQ (infigratinib), were approved by the FDA in February and May 2021, and that product sales have not been significant to date. Balance sheet and financing: cash, cash equivalents and marketable securities were $599.6 million at September 30, 2021, and total liabilities were $1.52 billion against total stockholders' deficit of $(738.8) million. Outstanding debt included $747.5 million of 2.25% convertible notes due 2029 issued in January 2021 and $550.0 million of 2.50% convertible notes due 2027, plus $100.0 million of Hercules term loan borrowings. Net cash used in operating activities was $364.0 million for the nine months. The company stated that its cash and marketable securities are expected to fund operations for at least the next 12 months. Other developments in the period include the January 2021 closing of the Eidos merger, which consideration of $1,651.6 million (cash of $21.3 million and about 26.2 million shares), a $150.0 million share repurchase program completed under authorization approved in May 2021, and a subsequent event in which LianBio completed its IPO on November 1, 2021, leaving BridgeBio with an estimated 4.7% equity interest.
- 2021-Q2Aug 5, 2021
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2021
BridgeBio Pharma, Inc. reported a net loss of $102.1 million for the three months ended June 30, 2021 and $273.2 million for the six months ended June 30, 2021, compared with $136.2 million and $240.3 million in the same periods of 2020. Total revenue for the second quarter was $54.0 million, consisting mainly of $53.0 million in license revenue tied to the QED-Helsinn License and Collaboration Agreement and the Navire-LianBio License Agreement, plus $1.0 million in initial product sales of Truseltiq and Nulibry. Research and development expense rose to $102.0 million in the quarter and $224.5 million for the six months, while selling, general and administrative expense was $46.0 million and $91.4 million, respectively. As of June 30, 2021, the company held cash, cash equivalents and marketable securities of $898.4 million, up from $607.1 million at December 31, 2020, and reported outstanding debt of $1,373.9 million net of discounts and issuance costs. The increase in liquidity reflects the January 2021 issuance of $747.5 million principal amount of 2.25% convertible senior notes due 2029, a $25.0 million additional term loan under the amended Hercules facility, and a $20.0 million upfront payment from Helsinn. Net cash used in operating activities was $242.5 million for the six months, and management states it expects existing resources to fund operations for at least the next 12 months. The January 26, 2021 merger with Eidos Therapeutics made Eidos a wholly owned subsidiary, with the purchase of the Eidos noncontrolling interest settled for an aggregate consideration of $1,651.6 million. Total stockholders' equity (deficit) was $(457.5) million at June 30, 2021, compared with $106.3 million at December 31, 2020, reflecting the accumulated deficit of $1,133.9 million and the recorded Eidos transaction effects in additional paid-in capital. The LEO call option was terminated effective April 15, 2021, and PellePharm was consolidated from that date.
- 2021-Q1May 6, 2021
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2021
BridgeBio Pharma, Inc. ("BridgeBio") reported a net loss of $171.1 million for the three months ended March 31, 2021, compared with $104.1 million in the prior-year period. Loss from operations was $167.5 million, driven by research and development expenses of $122.6 million (up from $68.2 million) and general and administrative expenses of $45.4 million (up from $34.3 million). License revenue was $462 thousand, and the company has no approved products and no product sales. Net loss attributable to common stockholders of BridgeBio was $163.1 million, or $1.18 per share. Liquidity was strengthened during the quarter. Cash, cash equivalents and marketable securities totaled $1,001.3 million at March 31, 2021, up from $607.1 million at December 31, 2020. The increase reflects the January 2021 issuance of $747.5 million principal of 2.25% convertible senior notes due 2029, with net proceeds of approximately $731.4 million. Total outstanding debt was $1,364.8 million net of discounts and issuance costs. Management stated that cash and marketable securities are expected to fund operations for at least the next 12 months. Net cash used in operating activities was $150.8 million for the quarter. The January 26, 2021 merger with Eidos Therapeutics, Inc. made Eidos a wholly-owned subsidiary. BridgeBio acquired the outstanding Eidos common stock for aggregate consideration of $1,651.6 million, comprising cash of $21.3 million and about 26.2 million shares of common stock. Stockholders' equity was a deficit of $389.4 million at March 31, 2021, compared with equity of $106.3 million at December 31, 2020, largely because of the accounting for the Eidos transaction. Subsequent to quarter end, the company amended its Hercules loan, providing an additional $25.0 million advance.
- 2020-Q3Nov 5, 2020
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2020
BridgeBio Pharma, Inc. (BBIO) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2020. The company reported license revenue of $8.1 million for the three and nine months ended September 30, 2020, compared with $26.7 million in the same periods of 2019, and a net loss of $130.2 million for the quarter and $370.5 million for the nine months. Research and development expense was $92.1 million for the quarter and $246.9 million for the nine months, while general and administrative expense was $36.0 million and $108.2 million, respectively. Net loss per share was $0.98 for the quarter and $2.79 for the nine months. The company describes itself as a clinical-stage biopharmaceutical company with no approved products and an accumulated deficit of $768.8 million as of September 30, 2020. Liquidity is described as cash, cash equivalents and marketable securities of $710.7 million as of September 30, 2020, of which $563.4 million excludes Eidos Therapeutics, Inc., a majority-owned subsidiary whose cash may only be used for Eidos. In March 2020 the company issued $550.0 million of 2.50% Convertible Senior Notes due 2027, with net proceeds of approximately $537.0 million, of which about $49.3 million funded capped call transactions and about $75.0 million funded a share repurchase. Management states that cash and marketable securities are expected to fund operations for at least the next 12 months. Net cash used in operating activities was $303.5 million for the nine months. Subsequent to the quarter, on October 5, 2020, the company agreed to acquire the outstanding shares of Eidos it does not already own, with Eidos holders able to elect 1.85 BridgeBio shares or $73.26 in cash per share, subject to a $175.0 million cap on aggregate cash consideration. The filing notes the company expects to complete the transaction in the first quarter of 2021, and that it will cease to be an emerging growth company on December 31, 2020. The filing also reports that COVID-19 has caused delays in or temporary suspension of enrollment in some clinical trials.
- 2020-Q2Aug 11, 2020
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2020
BridgeBio Pharma, Inc. reported a net loss of $136.2 million for the three months ended June 30, 2020 and $240.3 million for the six months ended June 30, 2020, compared with $74.3 million and $143.8 million in the same periods of 2019. Operating expenses rose on higher research and development ($86.6 million for the quarter, up from $52.3 million) and general and administrative costs ($38.0 million, up from $17.0 million). The company has no approved products and has generated no product revenue. As of June 30, 2020, it held cash, cash equivalents and marketable securities of $840.9 million, of which $666.1 million excluded Eidos Therapeutics, a majority-owned subsidiary. Management states these resources should fund operations for at least the next 12 months. The balance sheet changed mainly because of the March 2020 issuance of $550.0 million of 2.50% Convertible Senior Notes due 2027, which had a net carrying amount of $373.7 million at quarter end. The company used about $49.3 million for capped call transactions and about $75.0 million to repurchase 2,414,681 common shares. Total debt was $466.6 million net of discounts and issuance costs. Operating cash outflow for the six months was $171.8 million. The filing also discloses that COVID-19 has caused delays in or temporary suspension of enrollment in some ongoing clinical trials, and that the impact remains unknown. Subsequent events include a July 2020 $350.0 million at-the-market equity program, which the company had not used through August 11, 2020, and an August 9, 2020 exclusive license with LianBio for the BBP-398 SHP2 inhibitor, providing an $8.0 million upfront payment and up to $382.1 million in milestones. The company expects to cease being an emerging growth company on December 31, 2020.
- 2020-Q1May 14, 2020
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2020
BridgeBio Pharma, Inc. (BBIO) reported its Form 10-Q for the quarter ended March 31, 2020. The company, which has no approved products and no product revenue, recorded a net loss of $104.1 million for the three months ended March 31, 2020, compared with $69.4 million in the prior-year period. Research and development expense rose to $68.2 million from $44.9 million, and general and administrative expense rose to $34.3 million from $18.9 million, driven by headcount growth and public-company compliance costs. Net loss attributable to common stockholders of BridgeBio was $91.9 million, or $0.78 per share. The balance sheet strengthened substantially during the quarter. Cash and cash equivalents rose to $757.0 million from $363.8 million at year-end 2019, and total cash, cash equivalents and marketable securities were $928.4 million, or $731.9 million excluding Eidos Therapeutics, Inc., a majority-owned subsidiary. The increase was driven mainly by the March 2020 issuance of $550.0 million of 2.50% Convertible Senior Notes due 2027, with net proceeds of approximately $537.0 million. Part of those proceeds funded $49.3 million of capped call transactions and a $75.0 million repurchase of 2,414,681 common shares. The company stated that its cash and marketable securities should fund operations for at least the next 12 months. The filing also flags COVID-19 as a near-term operational risk. The company reported delays in patient enrollment and planned trial starts, and it revised timelines for several programs, including the Phase 3 ATTRibute-CM study of BBP-265, topline data for BBP-589, and a Phase 2/3 trial of zuretinol. The company said it expects to complete a rolling NDA for fodsdenopterin in 2020 and to submit an NDA for infigratinib in 2020. Total debt was $461.3 million on the balance sheet, net of discounts and issuance costs.
- 2019-Q3Nov 8, 2019
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2019
BridgeBio Pharma, Inc. (BBIO) filed this Form 10-Q for the quarter ended September 30, 2019, its first quarterly report after its July 1, 2019 IPO, in which it sold 23,575,000 shares at $17.00 per share for net proceeds of approximately $366.2 million. As of September 30, 2019, the company held cash, cash equivalents and marketable securities of $611.9 million, of which $446.1 million was held at the BridgeBio group excluding Eidos and $165.8 million at Eidos. The company reported no product revenue; its only revenue in the period was $26.7 million of license revenue recognized from the September 2019 Alexion agreements with Eidos. Net loss was $60.7 million for the three months and $204.4 million for the nine months ended September 30, 2019, versus $42.1 million and $120.2 million in the prior-year periods. Research and development expense rose to $55.3 million for the quarter and $152.5 million for the nine months, and general and administrative expense rose to $23.5 million and $59.4 million, reflecting expansion of controlled entities and development programs. The company states that its cash and equivalents, together with IPO proceeds, will fund operations for at least 24 months, and it reports working capital of $518.3 million. Its term debt under the Amended Hercules Term Loan totals $75.0 million, with interest-only payments through July 1, 2021 and a maturity date of January 1, 2023. The filing discloses that material weaknesses in internal control over financial reporting identified for 2017 had not been remediated as of September 30, 2019, and that Eidos reported a separate material weakness. The company also discloses a non-binding August 2019 proposal to acquire the Eidos shares it did not own, which subsequently terminated discussions. The filing describes a pipeline of over 15 development programs, with four product candidates in clinical trials, two of them in Phase 3. Key programs include BBP-265 (Eidos, ATTR amyloidosis), BBP-831 (QED), BBP-454 (TheRas) and BBP-631 (Adrenas). The company also discloses that LEO holds an option to acquire PellePharm, which was deconsolidated in November 2018, and that PellePharm losses of $16.1 million were recorded for the nine months.
- 2019-Q2Aug 14, 2019
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2019
BridgeBio Pharma, Inc. (the "Corporation") filed this Form 10-Q for the quarter ended June 30, 2019. The Corporation was formed on May 17, 2019 to complete an IPO and reorganize BridgeBio Pharma LLC, and its own balance sheet is essentially empty as of June 30, 2019, with only $69 thousand of stock-based compensation and net loss. The IPO closed on July 1, 2019, selling 23,575,000 shares at $17.00 per share for net proceeds of approximately $366.3 million, and BridgeBio Pharma LLC became a wholly-owned subsidiary. The substantive financial information is in BridgeBio Pharma LLC's condensed consolidated statements. For the six months ended June 30, 2019, the LLC reported a net loss of $143.7 million (versus $78.1 million in 2018), with research and development expense of $97.2 million and general and administrative expense of $35.8 million. Cash and cash equivalents were $293.8 million at June 30, 2019, of which $112.4 million was held at BridgeBio and $131.4 million at Eidos, and the accumulated deficit was $326.1 million. The company states it has no approved products and no product revenue, and it expects its cash plus IPO proceeds to fund operations for at least 24 months. Key operating developments include a $75.0 million Hercules term loan following a May 2019 amendment, the consolidation of Eidos Therapeutics, Inc. under the voting interest model with a 65.1% ownership stake, and a deconsolidated PellePharm investment that generated a $9.6 million loss for the six months. The LEO call option liability rose to $4.3 million, and the company recorded $1.3 million of expense from its remeasurement. The filing also discloses a non-binding proposal, submitted August 8, 2019, to acquire the Eidos shares it does not own at a fixed exchange ratio of 1.30 BridgeBio shares per Eidos share. The company reports ongoing material weaknesses in internal control over financial reporting that had not been remediated as of June 30, 2019. The filing describes a clinical-stage portfolio of more than 15 development programs, with four product candidates in clinical trials, two of which are in Phase 3. The company describes its R&D spending as increasing substantially, driven by Phase 3 trials for BBP-265 and planned Phase 3 trials for BBP-831.